Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in white and Asian patients with diabetes: a systematic review and meta-analysis of …
BACKGROUND The pathophysiology of type 2 diabetes differs markedly by ethnicity.
PURPOSE A systematic review and meta-analysis was conducted to assess the impact of …
PURPOSE A systematic review and meta-analysis was conducted to assess the impact of …
Comparative cardiovascular outcomes of SGLT2 inhibitors in type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials
Y Jiang, P Yang, L Fu, L Sun, W Shen… - Frontiers in …, 2022 - frontiersin.org
Background A network meta-analysis of randomized controlled trials (RCTs) was conducted
to explore the cardiovascular outcomes of all the kind and dosages of sodium-glucose …
to explore the cardiovascular outcomes of all the kind and dosages of sodium-glucose …
Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by a
progressive increase in pulmonary vascular resistance, ultimately leading to right heart …
progressive increase in pulmonary vascular resistance, ultimately leading to right heart …
Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis
Background This review evaluated the efficacy and safety of a combination therapy
comprising a sodium-glucose cotransporter type 2 inhibitor (SGLT2i) and dipeptidyl …
comprising a sodium-glucose cotransporter type 2 inhibitor (SGLT2i) and dipeptidyl …
Dipeptidyl peptidase‐4 inhibitors moderate the risk of genitourinary tract infections associated with sodium‐glucose co‐transporter‐2 inhibitors
GP Fadini, BM Bonora, S Mayur… - Diabetes, Obesity …, 2018 - Wiley Online Library
Genitourinary tract infections (GUTIs) are the most common adverse event (AE) occurring
during therapy with sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors. We evaluated …
during therapy with sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors. We evaluated …
Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: glycaemic efficacy and safety profile in a 52‐week …
R Kawamori, M Haneda, K Suzaki… - Diabetes, Obesity …, 2018 - Wiley Online Library
Aims This double‐blind, randomized, placebo‐controlled trial (ClinicalTrials. gov
NCT02453555) evaluated the efficacy and safety of empagliflozin (Empa) 10 or 25 mg as …
NCT02453555) evaluated the efficacy and safety of empagliflozin (Empa) 10 or 25 mg as …
Dipeptidyl peptidase‐4 inhibitor treatment and the risk of bullous pemphigoid and skin‐related adverse events: a systematic review and meta‐analysis of randomized …
W Yang, X Cai, S Zhang, X Han… - … Metabolism Research and …, 2021 - Wiley Online Library
Aims This meta‐analysis aimed to evaluate the risk of developing bullous pemphigoid (BP)
and other skin‐related adverse events (AEs) in patients with type 2 diabetes (T2DM) …
and other skin‐related adverse events (AEs) in patients with type 2 diabetes (T2DM) …
Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double‐blind, controlled 26‐week trial (RELEASE)
SA de Boer, HJL Heerspink… - Diabetes, Obesity …, 2017 - Wiley Online Library
Aims To evaluate the effects of the dipeptidyl peptidase‐4 (DPP‐4) inhibitor linagliptin on
aortic pulse wave velocity (PWV) as a surrogate marker of arterial stiffness and early …
aortic pulse wave velocity (PWV) as a surrogate marker of arterial stiffness and early …
Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes
I Lingvay, N Beetz, R Sennewald… - Postgraduate …, 2020 - Taylor & Francis
Objectives Fixed-dose combination (FDC) therapy can improve outcomes in type 2 diabetes
(T2D). We evaluated the bioequivalence of 2 doses of an FDC of extended-release …
(T2D). We evaluated the bioequivalence of 2 doses of an FDC of extended-release …
SGLT2 inhibitor/DPP-4 inhibitor combination therapy–complementary mechanisms of action for management of type 2 diabetes mellitus
J Dey - Postgraduate medicine, 2017 - Taylor & Francis
Type 2 diabetes mellitus is a progressive disease with multiple underlying pathophysiologic
defects. Monotherapy alone cannot maintain glycemic control and leads to treatment failure …
defects. Monotherapy alone cannot maintain glycemic control and leads to treatment failure …